A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...